- Home
- NVCR vs TLRY Comparison
NVCR vs TLRY Comparison
Compare NVCR & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- TLRY
- Stock Information
- Founded
- NVCR 2000
- TLRY N/A
- Country
- NVCR Switzerland
- TLRY Canada
- Employees
- NVCR N/A
- TLRY N/A
- Industry
- NVCR Medical/Dental Instruments
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- NVCR Health Care
- TLRY Health Care
- Exchange
- NVCR Nasdaq
- TLRY Nasdaq
- Market Cap
- NVCR 1.9B
- TLRY 502.9M
- IPO Year
- NVCR 2015
- TLRY 2018
- Fundamental
- Price
- NVCR $18.02
- TLRY $0.41
- Analyst Decision
- NVCR Buy
- TLRY Hold
- Analyst Count
- NVCR 6
- TLRY 2
- Target Price
- NVCR $32.83
- TLRY $1.38
- AVG Volume (30 Days)
- NVCR 1.8M
- TLRY 29.1M
- Earning Date
- NVCR 07-24-2025
- TLRY 07-28-2025
- Dividend Yield
- NVCR N/A
- TLRY N/A
- EPS Growth
- NVCR N/A
- TLRY N/A
- EPS
- NVCR N/A
- TLRY N/A
- Revenue
- NVCR $621,711,000.00
- TLRY $826,656,000.00
- Revenue This Year
- NVCR $5.56
- TLRY $9.91
- Revenue Next Year
- NVCR $9.19
- TLRY $5.94
- P/E Ratio
- NVCR N/A
- TLRY N/A
- Revenue Growth
- NVCR 18.27
- TLRY 11.22
- 52 Week Low
- NVCR $14.17
- TLRY $0.35
- 52 Week High
- NVCR $34.13
- TLRY $2.15
- Technical
- Relative Strength Index (RSI)
- NVCR 47.07
- TLRY 49.33
- Support Level
- NVCR $16.19
- TLRY $0.35
- Resistance Level
- NVCR $18.02
- TLRY $0.42
- Average True Range (ATR)
- NVCR 0.88
- TLRY 0.02
- MACD
- NVCR -0.04
- TLRY 0.00
- Stochastic Oscillator
- NVCR 29.74
- TLRY 55.91
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.